This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

This study has suspended participant recruitment.
Information provided by:
AstraZeneca Identifier:
First received: July 28, 2003
Last updated: January 25, 2011
Last verified: January 2011
The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

Condition Intervention Phase
Carcinoma, Renal Cell Kidney Neoplasms Drug: ZD6126 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Study Start Date: August 2003
Estimated Study Completion Date: February 2004
Estimated Primary Completion Date: February 2004 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Newly diagnosed metastatic renal cell carcinoma
  • Suitable for nephrectomy

Exclusion Criteria:

  • Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
  • Significant cardiac event within 3 months of entry
  • Any history of coronary angioplasty or history of myocardial infarction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00065572

United States, California
Research Site
Los Angeles, California, United States
United States, Delaware
Research Site
Newark, Delaware, United States
United States, Florida
Research Site
Tampa, Florida, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
United States, Indiana
Research Site
Indianapolis, Indiana, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
United States, Missouri
Research Site
St. Louis, Missouri, United States
United States, New Hampshire
Research Site
Lebanon, New Hampshire, United States
United States, New Jersey
Research Site
Hackensack, New Jersey, United States
United States, New York
Research Site
Bronx, New York, United States
Research Site
Rochester, New York, United States
United States, Ohio
Research Site
Cleveland, Ohio, United States
United States, Oregon
Research Site
Portland, Oregon, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
United States, Utah
Research Site
Salt Lake City, Utah, United States
Sponsors and Collaborators
  More Information Identifier: NCT00065572     History of Changes
Other Study ID Numbers: D2820C00018
Study First Received: July 28, 2003
Last Updated: January 25, 2011

Keywords provided by AstraZeneca:
Kidney Cancer
Newly diagnosed renal cell carcinoma

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases processed this record on September 19, 2017